JDRF and Novo Nordisk have announced that they are partnering in an attempt to discover and develop novel immunotherapies to prevent, treat, and help cure type 1 diabetes. The collaboration between JDRF and Novo Nordisk will focus on research originating from academia, biotechnology companies and from internal research projects at Novo Nordisk.
The collaboration with Novo Nordisk will be run out of the company’s newly opened Type 1 Diabetes R&D Center in Seattle. The Center, led by Dr. Matthias von Herrath, plans to employ 20 immunotherapy researchers working in Seattle and supported by corporate R&D functions in Princeton, NJ and Denmark. The Center’s goal is to use translational research methods to rapidly move early-stage discovery projects in immunotherapy from animal models into small clinical exploratory trials in type 1 diabetes.